EE200300408A - Aktiivsete valkude saagise suurendamine - Google Patents

Aktiivsete valkude saagise suurendamine

Info

Publication number
EE200300408A
EE200300408A EEP200300408A EEP200300408A EE200300408A EE 200300408 A EE200300408 A EE 200300408A EE P200300408 A EEP200300408 A EE P200300408A EE P200300408 A EEP200300408 A EE P200300408A EE 200300408 A EE200300408 A EE 200300408A
Authority
EE
Estonia
Prior art keywords
increasing
yield
active proteins
proteins
preparations
Prior art date
Application number
EEP200300408A
Other languages
English (en)
Inventor
M. Sassenfeld Helmut
L. Remmele Richard Jr.
E. Mccoy Rebecca
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of EE200300408A publication Critical patent/EE200300408A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Measurement Of Radiation (AREA)
EEP200300408A 2001-02-23 2002-02-22 Aktiivsete valkude saagise suurendamine EE200300408A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27103301P 2001-02-23 2001-02-23
PCT/US2002/005645 WO2002068455A2 (en) 2001-02-23 2002-02-22 Efficient recovery of correctly refolded proteins

Publications (1)

Publication Number Publication Date
EE200300408A true EE200300408A (et) 2003-12-15

Family

ID=23033913

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300408A EE200300408A (et) 2001-02-23 2002-02-22 Aktiivsete valkude saagise suurendamine

Country Status (21)

Country Link
US (2) US7157557B2 (et)
EP (1) EP1366062B1 (et)
JP (1) JP2005505494A (et)
KR (1) KR20040052481A (et)
CN (1) CN1547586A (et)
AT (1) ATE517909T1 (et)
AU (1) AU2002255600B2 (et)
BG (1) BG108087A (et)
CA (1) CA2438094C (et)
CZ (1) CZ20032208A3 (et)
EE (1) EE200300408A (et)
ES (1) ES2370235T3 (et)
HK (1) HK1059267A1 (et)
HU (1) HUP0303246A2 (et)
IL (1) IL157446A0 (et)
MX (1) MXPA03007563A (et)
PL (1) PL374045A1 (et)
RU (1) RU2316563C2 (et)
SK (1) SK10472003A3 (et)
WO (1) WO2002068455A2 (et)
ZA (1) ZA200305909B (et)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007563A (es) * 2001-02-23 2003-12-11 Immunex Corp Recuperacion incrementada de proteinas activas.
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP1805205A1 (en) * 2004-10-22 2007-07-11 Amgen Inc. Methods for refolding polypeptides
US7928205B2 (en) * 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
JP2008528006A (ja) * 2005-01-28 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
CA2607663C (en) 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
EP1893632B1 (en) * 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP5036727B2 (ja) 2005-12-22 2012-09-26 ジェネンテック， インコーポレイテッド ヘパリン結合タンパク質の組み換え体産生
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
BRPI0713252C1 (pt) 2006-07-14 2021-05-25 Genentech Inc processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
PT3597659T (pt) 2007-07-09 2023-04-04 Genentech Inc Prevenção da redução de ligações de dissulfureto durante a produção recombinante de polipéptidos
EP2197911A2 (en) * 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
AU2010270986B2 (en) 2009-06-22 2014-05-22 Amgen Inc. Refolding proteins using a chemically controlled redox state
ES2862580T5 (es) 2009-06-25 2024-06-13 Amgen Inc Procesos de purificación por captura para proteínas expresadas en un sistema no de mamífero
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
RU2012127383A (ru) * 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
PL2673296T3 (pl) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
KR20200044138A (ko) 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
CN104508133B (zh) 2012-08-02 2018-04-20 弗·哈夫曼-拉罗切有限公司 用于产生单体和多聚体分子的方法及其用途
CN110051823A (zh) 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
BR112015021495A2 (pt) 2013-03-08 2017-07-18 Genzyme Corp fabricação contínua integrada de substâncias de droga de proteína terapêutica
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
US11369703B2 (en) 2018-08-31 2022-06-28 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method
CN118047854A (zh) * 2024-02-26 2024-05-17 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
EP0293785A3 (en) 1987-05-29 1990-05-02 Oncogen Limited Partnership Cloning and expression of simian transforming growth factor-ss1
US4970067A (en) * 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU648214B2 (en) * 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0663009A1 (en) * 1993-08-04 1995-07-19 Novartis AG High molecular weight desulphatohirudin
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995032216A1 (en) * 1994-05-25 1995-11-30 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
CZ283219B6 (cs) * 1994-07-22 1998-02-18 F. Hoffmann-La Roche Ag Použití chimerního proteinu vázajícího TNF pro výrobu farmaceutického prostředku k ošetřování autoimunních nemocí
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) * 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
MXPA03007563A (es) * 2001-02-23 2003-12-11 Immunex Corp Recuperacion incrementada de proteinas activas.

Also Published As

Publication number Publication date
MXPA03007563A (es) 2003-12-11
ES2370235T3 (es) 2011-12-13
PL374045A1 (en) 2005-09-19
US7157557B2 (en) 2007-01-02
SK10472003A3 (sk) 2004-03-02
WO2002068455A2 (en) 2002-09-06
IL157446A0 (en) 2004-03-28
CA2438094A1 (en) 2002-09-06
AU2002255600B2 (en) 2008-01-24
HUP0303246A2 (hu) 2003-12-29
CA2438094C (en) 2011-10-11
BG108087A (bg) 2005-04-30
US7544784B2 (en) 2009-06-09
EP1366062B1 (en) 2011-07-27
US20070270577A1 (en) 2007-11-22
RU2003127830A (ru) 2005-04-10
ZA200305909B (en) 2004-06-04
KR20040052481A (ko) 2004-06-23
JP2005505494A (ja) 2005-02-24
US20020182665A1 (en) 2002-12-05
ATE517909T1 (de) 2011-08-15
HK1059267A1 (en) 2004-06-25
RU2316563C2 (ru) 2008-02-10
WO2002068455A3 (en) 2003-09-18
EP1366062A2 (en) 2003-12-03
CN1547586A (zh) 2004-11-17
CZ20032208A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
EE200300408A (et) Aktiivsete valkude saagise suurendamine
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
DK1641483T3 (da) Fusionsproteiner
AR038568A1 (es) Anticuerpos anti-a beta y su uso
DE60037450D1 (de) Funf-helix protein
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
DK1412503T3 (da) Et fusionsprotein
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
WO2003022883A3 (de) Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
AU2013245463B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2003280359A1 (en) Phosphoamidase assay
WO2003048320A3 (en) Novel motor protein of p. falciparum and methods for its use